Momenta Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Revenue Guidance for the Fourth Quarter 2018
For the nine months, total collaboration revenue was $32,767,000 against $74,274,000 a year ago. Loss from operations was $171,657,000 against $105,184,000 a year ago. Net loss was $167,816,000 against $101,855,000 a year ago. Basic and diluted net loss per share was $2.20 against $1.40 a year ago.
The company expects to continue to recognize revenue from Mylan's $45 million upfront payment on a quarterly basis. The company also estimates that collaborative reimbursement revenues will be approximately $0 million to $2 million in the fourth quarter of 2018.